Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $48
Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $35 to $48.
SVB Leerink Maintains Outperform on Amylyx Pharma, Raises Price Target to $50
SVB Leerink analyst Marc Goodman maintains Amylyx Pharma (NASDAQ:AMLX) with a Outperform and raises the price target from $31 to $50.
Amylyx Pharmaceuticals Announced FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") announced today that the U.S.
FDA Again Highlights Lacking Data From Amylyx’s Amyotrophic Lateral Sclerosis Candidate
The FDA released briefing documents for Amylyx Pharmaceuticals Inc’s (NASDAQ:AMLX) experimental amyotrophic lateral sclerosis drug, as a second adcomm is scheduled…
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers
Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.
Amylyx Pharmaceuticals Announces Posting Of Briefing Documents For Second FDA Advisory Committee Meeting On AMX0035
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx or the "Company") today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the reconvened Peripheral and Central
FDA Briefing Document On Amylyx Pharmaceuticals’ AMX0035 Says ‘it does not appear that this data can be considered independent confirmatory evidence as it uses the same data as the primary analysis.’
FDA Position:
This post hoc analysis is highly correlated with the primary analysis. Both change from
baseline slope and pre-study slope were used in the primary analysis; thus, this is not
independent data. Therefore,
FDA Briefing Document For Amylyx Pharmaceuticals’ AMX0035 (Full document)
https://www.fda.gov/media/161378/download
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Citigroup Maintains Buy on Amylyx Pharma, Raises Price Target to $37
Citigroup analyst Neena Bitritto-Garg maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $33 to $37.